Stem cell-based therapy is emerging as a promising strategy to treat end-stage heart failure, a leading cause of morbidity and mortality. Stem cells can be isolated from a variety of sources and exhibit unique characteristics that impact their potential therapeutic utility. The adult heart contains small populations of committed, multipotent cardiac stem cells (CSC), which are adapted to the cardiac microenvironment and participate in postnatal physiological and pathological cardiac renewal or repair. These cells can be isolated, expanded in culture, and administered therapeutically to improve cardiac function in the setting of heart failure. CSC can be differentiated into three distinct cardiovascular lineages and exhibit enhanced paracrine factor production and engraftment as compared with other types of mesenchymal stem cells, which in turn may translate into improved therapeutic efficacy. The cell surface marker expression and phenotype of these CSC, however, depends on the method of isolation, selection and propagation, which likely explains the variable experimental results obtained to date. Moreover, invasive procedures are required to obtain CSC from humans. Early trials using autologous CSC in patients with ischemic cardiomyopathy have demonstrated feasibility and safety, along with variable degrees of therapeutic efficacy in terms of enhancing myocardial viability and cardiac function. Further studies are needed to optimize methods of CSC isolation, manipulation and delivery. If fully realized, the potential of CSC therapy could fundamentally change the approach to the treatment of end-stage heart failure.
Introduction
Congestive heart failure is a leading cause of morbidity and mortality worldwide. Approximately 5.7 million Americans have heart failure, and it is responsible for 55,000 deaths and 34 billion dollars in health-care expenditures annually. 1, 2 Despite advances in medical therapy, mechanical support and heart transplantation, nearly half of all patients with heart failure die within five years of the initial diagnosis. Consequently, there is a great deal of interest in devising novel approaches, including stem cell therapy, to treat patients with advanced heart failure. Transplantation of bone marrow-derived cells can marginally improve cardiac function in animals and humans with heart failure, 3 -6 but the mechanisms for this functional improvement are unclear. Transdifferentiation into cardiomyocytes appears to be limited, and most of the cells disappear from the myocardium within one week of transplantation. 7 Evidence is emerging that the beneficial effects seen in these studies may be linked to stimulation of endogenous cardiogenic stem cells (CSC). 8 Moreover, CSC can be isolated from the heart, expanded in culture, and used as a source of stem cells to elicit cardiac repair. In this article, we will describe the populations of resident CSC, discuss their potential for heart repair, and summarize the limited clinical experience to date using these cells.
Cardiac stem cells
The adult mammalian heart is not a terminally differentiated organ, but harbors stem cells with replicative and regenerative capacity. 9 Many laboratories have reported the existence of an endogenous population of CSC in the adult heart. 10 Although efforts to compare and identify a true residing CSC population continue, the characteristics that define a CSC include self-renewal in a clonal fashion and multipotent capacity to differentiate into multiple cardiovascular lineages, including cardiomyocytes, smooth muscle cells and endothelial cells, both in vitro and in vivo. 11 Different biomarkers have been used to isolate and classify CSC. From the literature, it is difficult to effectively compare and determine which stem cell markers best identify CSC for optimal heart regeneration, as discrepancies exist in the methods of isolation and expansion ex vivo. A variety of methodologies have been described to isolate CSC, including fluorescence or magnetic activated cell sorting based on the expression of one or more specific cell surface markers, 12, 13 isolation of cardiac-derived cells with aggregational properties (i.e. cardiospheres) 14 -16 and more sophisticated approaches, such as genetic knock-in of reporter genes, to isolate Islet-1 (Isl-1) þ cardiac progenitors. 17 -19 In addition, the antigens that are targeted for the isolation of specific CSC populations also vary between laboratories; expression of various surface markers, such as Sca-1, c-kit, ABCG2, have been used to purify CSC from heart tissues. Moreover, the heterogeneity of CSC is underscored by studies that demonstrate variable growth and transdifferentiation potentials of different CSC populations, even individually expanded CSC clones. As a consequence, novel approaches such as microfluidic technology 20 may be useful to enrich a target cell type from a heterogenous cell population in order to select a CSC that is optimally suited for efficient heart repair.
Source of CSC and their potential for heart repair
Although the origins of CSC are yet unclear, they can be isolated from heart tissue and expanded ex vivo for use as a cell-based therapy. The fact that they are already adapted to the cardiac microenvironment is an obvious advantage of CSC in the cell-based treatment of heart failure. 12 It is important to acknowledge, however, that CSC constitutes a spectrum of cell types, with distinct features and functional capabilities, dependent in part upon the methods of isolation (summarized in Table 1 ). Moreover, most of the functional studies conducted to date utilize rodent models of myocardial infarction in young, healthy animals. These studies may not be directly translatable to aged humans with multisystem diseases. Therefore, the superiority of CSC over other stem cells for cardiac repair remains debatable at this point. Here, we will review the basic research conducted to date involving isolation and characterization of the different populations of CSC.
Cardiac Sca-1 1 cells
Sca-1 þ cells are endogenous CSC which can be isolated from the adult heart and transdifferentiated into cardiomyocytes, endothelial cells and smooth muscle cells in vitro. 15 Cardiac Sca-1 cells administered after ischemia/reperfusion can home to injured myocardium and the infarct border zone and differentiate into cardiomyocytes. 13, 24 Wang et al. 25 reported that transplantation of Sca-1(þ)/CD31(2) cells into the acutely infarcted mouse heart attenuated the functional decline and adverse structural re-modeling after experimental myocardial infarction (MI), as evidenced by an increased left ventricular (LV) ejection fraction, decreased LV end-systolic and end-diastolic dimensions, increased myocardial neovascularization and modest cardiomyocyte regeneration. Furthermore, genetic deletion of Sca-1 causes primary cardiac defects in myocardial repair consistent with impairment of resident cardiac progenitor cell proliferative capacity. 26 
Cardiac c-kit 1 cells
Cardiac c-kit þ cells, initially reported by Beltrami et al. 12 are self-renewing, clonogenic, multipotent cells, which give rise to myocytes, smooth muscle and endothelial cells. When cardiac c-kit cells are injected into ischemic heart tissue, these cells or their clonal progeny can reconstitute well-differentiated myocardium, formed by bloodcarrying vessels and myocytes with the characteristics of young cells. 12 The origin and significance of these cells has remained obscure. Sandstedt et al. 27 showed that c-kit þ CD45-cells express markers commonly found on endothelial progenitor cells and represent a population of endothelial progenitor cells in human heart. Hattori et al. 28 showed that c-kit þ cells represent a population of mesothelial epicardial cells, while Zhou et al. 29 reported that cardiac c-kit þ/CD45 (dim/moderate) progenitor cells may be mast cells. In addition, cardioprotective c-kit þ cells have been suggested to originate from the bone marrow and regulate the myocardial balance of angiogenic cytokines, including vascular endothelial growth factor and the angiopoietins. 30 There is also a dispute about the fate of c-kit þ precursors; evidence suggests that neonatal c-kit þ precursors support postinfarction myogenesis, while adult c-kit precursors only adopt a vascular fate within infarcted tissue, without differentiating into myocytes. 31 Thus, cardiac-resident c-kit progenitor cells in adult heart appear to represent a heterogenous population of cells with diverse origins, functions and differentiation capacity.
Cardiac side population cells
Side population (SP) cells can be isolated via a DNAbinding dye (Hoechst 33342 or rhodamine123) exclusion and dual wavelength flow cytometric analysis method. 32 SP cells have been isolated from multiple adult tissues, including bone marrow, liver, lung, skeletal muscle and adipose tissue. 33 -36 Adult hearts contain a subpopulation of SP cells which exhibit stem cell characteristics, and they have been shown to contribute to the development, maintenance and repair of the heart. 23, 37 SP cells express ATP-binding cassette transporter (Abcg2) and can differentiate into a-actinin-positive cardiomyocytes. These stem cells are classified as Sca1 high , cKit low , CD34 low and CD45 low cells. 23 In comparison with bone marrow SP cells, cardiac SP cells exhibit high expression of Afp, Ace,Bmp6, Cldn5, Dkk3, Eln, Fst, Foxc2, Tcf21 (capsulin), Sox17, Sox18, Rgs5, Meox1 and Meox2. 23 Using loss-and gain-of-function approaches, Pfister et al. 38 showed that Abcg2 tightly regulates cell fate and function. Genetic ablation of Abcg2 resulted in blunted proliferation capacity and augmented cell death, while over-expression of Abcg2 enhanced cell proliferation, although with limited cardiomyogenic differentiation. Cardiac SP cells, however, are not a pure cell population. Yamahara et al. 39 reported that cardiac SP cells consist of vascular endothelial cells, smooth muscle cells and mesenchymal stem cells, including potentially cardiomyogenic cells. Thus, SP cells are heterogeneous in nature, and their role in therapeutic heart regeneration remains to be determined.
Epicardium-derived cells
Recent studies reported the existence of progenitors in the pro-epicardium, 40 which express the T-box transcription factor (Tbx18), migrate onto the outer cardiac surface to form the epicardium, and then make a substantial contribution to myocytes in the ventricular septum and the atrial and ventricular walls during cardiac development. Epicardium-derived cells (EPDC) are also important for blood vessel formation. In Zebrafish, a subpopulation of these epicardial cells undergoes epithelial-to-mesenchymal transition (EMT), invades damaged tissues and provides new vasculature to regenerating muscle. 41 EMT might be a major mechanism for generation of cardiovascular progenitor cells that differentiate into cardiovascular lineages, including coronary smooth muscle and endothelial cells, as well as cardiomyocytes. Martinez-Estrada 42 reported that the gene encoding Wilms' tumor-1 (Wt1) is essential for repression of the epithelial phenotype in epicardial cells through direct transcriptional regulation of the genes encoding Snail (Snai1) and E-cadherin (Cdh1), two of the major mediators of EMT. Most recently, Smart et al. 43 reported that actin monomer-binding protein, thymosin beta-4 (Tbeta-4), a peptide which has been suggested to be critical for cardiac development and to have cardioprotective properties, is secreted from the ischemic heart and provides a paracrine stimulus to EPDC to promote their inward migration and differentiation into endothelial and smooth muscle cells to form coronary vasculature. Gajzer et al. 44 reported that priming EPDC with Tbeta-4 can also facilitate cardiomyocyte differentiation. Tbeta-4 was the subject of a multicenter phase 1 clinical trial for treatment of cardiovascular disease (http://www.regenerx. com), suggesting the potential clinical utility of this peptide. 43 Currently, EPDC do not have well-defined cell surface markers, which makes clinical application of EPDC challenging. Furthermore, the mechanism for cardiomyocyte differentiation of EPDC is poorly understood.
Cardiosphere-derived cardiac cells
Messina et al. 14 were first to demonstrate that cardiospherederived cardiac cells (CDC) can be clonally expanded from mouse and human myocardial biopsies and form cardiospheres, which express Sca-1, c-kit, Flk and CD31. The primary tissue explant technique facilitates the proliferation of endogenous CSC in vitro, which are present in limited numbers in the adult heart. However, cardiospheres contain a mixture of cells, including cardiac fibroblasts, which grow faster than endogenous CSC in the cardiosphere. Contamination of fibroblasts in cardiospheres would limit therapeutic utility because the fibroblasts could facilitate scar formation and hamper efficiency of heart repair. To solve this problem, our laboratory developed a two-step protocol to purify CDC from fibroblast contamination. 15 Reports from our and other groups show that Sca-1 þ CDC have clonogenic ability, form spheroid aggregates in culture and can differentiate into endothelial cells, smooth muscle cells and cardiomyocytes in ischemic heart after cell transplantation. 45 We also showed that c-kit þ CDC possess similar properties and can home to myocardium following ischemic injury. 46 Moreover, we showed that intravenously infused c-kit þ CDC can stimulate angiogenesis and improve LV function, 46 and that Notch1 activation can efficiently increase smooth muscle cell differentiation of Sca-1 þ CDC. 47 Shen et al. 48 demonstrated a dose-dependent functional benefit of intramyocardial injection of human cardiospheres into immunodeficient severe combined immunodeficiency mice with acute myocardial infarction. In a head-to-head comparison, transplanted CDC exhibited enhanced functional benefits as compared with other types of stem cells, which may relate to enhanced potency of paracrine factors that suppress apoptosis and induce angiogenesis, as well as increased engraftment and differentiation potential. 49 
Cardiac islet (Isl)-1 1 cells
The LIM-homeodomain transcription factor Islet-1 (Isl-1) marks a cell population which makes a substantial contribution to the embryonic heart. 18 After birth, immature Isl-1 þ cells localize in the proximal outflow tract, where a pool of these cells persists into adulthood. Islet-1-positive cells, which can represent both neural crest and cardiomyocyte lineages, are relatively few in number in the adult murine heart, and are localized in restricted and rather inaccessible areas. 19, 50 Domian et al. 51 further identified a committed ventricular progenitor cell in the Isl-1 lineage that is capable of limited in vitro expansion, differentiation and assembly into functional ventricular muscle tissue. Itzhaki-Alfia et al. compared CSC from atrial and ventricular tissue samples obtained during heart surgery, transplantation or endomyocardial biopsies (113 samples from 94 patients 23 -80 years of age). They found that the right atrium is the best source for Isl-1 progenitors, which are multipotent and can differentiate into osteoblasts, adipocytes and myogenic lineages. 52 Cardiospheres may represent an ideal intermediate stem cell niche for isolating any potential CSC, including Isl-1 þ cells. Ye et al. 45 reported that cloned Sca-1 þ cells derived from cardiospheres from infarcted middle aged hearts are enriched in Isl-1 þ precursors that give rise to both myocardial and vascular tissues. In summary, the adult heart contains CSC, the phenotype of which depends on the method of isolation. These CSC are multipotent and can be induced to differentiate into three cardiovascular lineages. In comparison with other tissue-derived stem cells, such as adipose tissueor bone marrow-derived mesenchymal stem cells, CSC offer several advantages that may lead to enhanced heart repair. The major disadvantages of CSC, however, include (1) an invasive procedure is required to obtain these cells; (2) the number of resident CSC declines in aging; and (3) successfully isolating CSC is technically challenging. Obtaining CSC from an allogeneic source might help to overcome these disadvantages. The CSC present in neonatal hearts exhibit robust regenerative capacity, 53 suggesting an ideal potential source of CSC for allogeneic transplantation.
Strategies to improve the efficiency of CSC transplantation
Although cardiac progenitor cells may seem to be an obvious choice for cell-based cardiac repair, as with other types of stem cells, the success of this approach is determined mainly by the survival of donor cells in diseased myocardium. In particular, the environment in ischemic myocardium is particularly harsh and represents a primary barrier to the effectiveness of cell therapy. Developing techniques that enhance the survival of transplanted CSC is crucial to adequately replenish the resident stem cell pool and to maximize its regenerative potential. 46 Our group has developed a hypoxia preconditioning (HPC) strategy, which induces CXCR4 expression in cardiospherederived, Lin-c-kit þ cells. We found that HPC markedly augments stem cell survival and recruitment to the ischemic myocardium in a CXCR4-dependent manner, thus enhancing the benefit of CDC therapy post-MI. 46 Recently, Yan et al., 54 testing a similar HPC strategy in CSC, found that HPC blunts apoptosis by regulating phosphorylated Akt and Bcl2.
MicroRNA (miRNAs) are endogenous 21 -22-nucleotide (nt) non-coding small RNAs that play a critical role in the coordinated fine-tuning of gene expression. 55 The precursor miRNAs must be processed to mature miRNAs by a series of steps directed by the enzyme Dicer. Mature miRNAs, Dicer and Argonaute proteins combine to form the miRNA-induced silencing complex (RISC). Guided by the miRNA through base-pairing, the RISC can suppress gene translation by binding to the 3 0 untranslated regions (3 0 UTR) of target genes. 56 Hu et al. 57 have showed that transducing Sca-1 þ CSC with a cocktail of lentiviruses expressing three miRNA precursors (miR-21, miR-24 and miR-221) significantly improved CSC survival both in vitro and in vivo. In addition, this cocktail of miRNAexpressing lentiviruses boosted the therapeutic efficacy of CSC transplantation in terms of functional cardiac recovery. 57 Therefore, targeting miRNAs offers completely new possibilities for improving the efficiency of CSC therapy.
Clinical trials using CSC
CSC are currently being evaluated in two clinical trials for patients with ischemic cardiomyopathy. The first study, Stem Cell Infusion in Patients with Ischemic cardiomyopathy (SCIPIO), evaluated the safety and feasibility of right atrial appendage-derived c-Kit þ CSC obtained at the time of open heart surgery. 58 Initial findings demonstrated that (1) isolation and ex vivo expansion of c-Kit þ CSC from about 1 g of myocardial tissue is feasible and reproducible and (2) intracoronary infusion of 1 million ex vivo expanded autologous CSC in patients with chronic ischemic cardiomyopathy and heart failure is feasible, safe and efficacious in restoring LV systolic function up to one year after treatment. A recent interim analysis of heart function by magnetic resonance imaging (MRI) in the SCIPIO patients showed that CSC infusion produces a striking improvement in both global and regional LV function, a reduction in infarct size, and an increase in viable tissue that persist at least one year post-treatment. 59 Further studies will be needed to determine the duration of this functional benefit, and to elucidate the underlying mechanisms (i.e. paracrine effects, activation of endogenous CSC and transdifferentiation). Furthermore, it is important to conduct additional studies using cardiac cells isolated with the same approach to replicate these encouraging results.
More recently, results of a prospective, randomized Phase 1 study of Cardiosphere-Derived Autologous Stem Cells to Reverse Ventricular Dysfunction (CADUCEUS) were reported. 60 Unlike SCIPIO, CADUCEUS employed CDC isolated from endomyocardial biopsy samples that yielded, on average, 276 mg of tissue per patient. Tissue explanting technology and suspension culture were used to obtain CDC, 95% of which expressed CD105 and 5% of which expressed CD45. In patients with systolic heart failure, CDC treatment resulted in significant reductions in scar mass and increases in viable heart tissue by MRI analysis. Regional contractility and regional systolic wall thickness were improved as well. Interestingly, end-diastolic volume, end-systolic volume and global LV ejection fraction did not differ between groups by six months. Further studies are needed to elucidate the precise mechanisms of actions of CDC in heart repair and, importantly, whether the new heart mass generated by donor cells can form electrical coupling with recipient cardiomyocytes, which might be critical for improvement of global cardiac contractility.
Summary
Multipotent CSC possess a vast therapeutic capacity and have shown potential in the treatment of heart failure in preclinical and some clinical settings. While it is clear that CSC do facilitate heart regeneration, the combination of optimal types of CSC with the appropriate delivery approach remains to be determined. Additional studies are required to resolve many other important issues, including determining the origins of CSC, standardizing isolation and purification protocols, and optimally manipulating the cells to enhance their survival in diseased myocardium. Future studies in small animal models should also be complemented by preclinical studies in large animal models that more closely mimic human heart disease. Resolving these issues should lead to improved efficacy of CSC and more consistent results in clinical trials, thus enabling us to understand the true therapeutic potential of CSC.
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